Clinical Trial Update: RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial of RAPA-201 T Cell Therapy for relapsed and refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• RAPA-201 T Cell Therapy

Snippet

Sponsor: Rapa Therapeutics LLC | Conditions: Relapsed, Refractory Multiple Myeloma | Phase 2 | Status: COMPLETED